ECSP034654A - Productos de hormona esteroide y metodos para preparar los mismos - Google Patents

Productos de hormona esteroide y metodos para preparar los mismos

Info

Publication number
ECSP034654A
ECSP034654A EC2003004654A ECSP034654A ECSP034654A EC SP034654 A ECSP034654 A EC SP034654A EC 2003004654 A EC2003004654 A EC 2003004654A EC SP034654 A ECSP034654 A EC SP034654A EC SP034654 A ECSP034654 A EC SP034654A
Authority
EC
Ecuador
Prior art keywords
methods
products
steroid hormone
hormone
excipient
Prior art date
Application number
EC2003004654A
Other languages
English (en)
Inventor
Thomas Schultz
Bradley Clark
Angela Falzone
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ECSP034654A publication Critical patent/ECSP034654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a productos de hormona esteroide, tales como productos anticonceptivos orales, que incluyen al menos un ingrediente activo esteroide mezclado con un excipiente y que tiene propiedades mejoradas de disolución y velocidad de liberación. La invención se refiere además a métodos para hacer tales productos de hormona esteroide, en los cuales una mezcle de la hormona y el excipiente es sometida a energía mecánica suficiente para formar una mezcla de polvo en el cual la hormona es estabilizada por el excipiente en forma sustancialmente no cristalina.
EC2003004654A 2000-12-14 2003-06-13 Productos de hormona esteroide y metodos para preparar los mismos ECSP034654A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25566900P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
ECSP034654A true ECSP034654A (es) 2003-07-25

Family

ID=22969374

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004654A ECSP034654A (es) 2000-12-14 2003-06-13 Productos de hormona esteroide y metodos para preparar los mismos

Country Status (30)

Country Link
US (4) US7867990B2 (es)
EP (2) EP1591121B1 (es)
KR (1) KR100899032B1 (es)
CN (1) CN1290507C (es)
AT (2) ATE307591T1 (es)
AU (2) AU2742102A (es)
BG (1) BG66178B1 (es)
BR (1) BRPI0116793B8 (es)
CA (1) CA2431521E (es)
CR (1) CR7022A (es)
CY (1) CY1109404T1 (es)
CZ (1) CZ306435B6 (es)
DE (2) DE60114467T2 (es)
DK (2) DK1591121T3 (es)
EC (1) ECSP034654A (es)
EE (1) EE05358B1 (es)
ES (2) ES2253451T3 (es)
HU (1) HU230400B1 (es)
IL (2) IL156423A0 (es)
ME (1) ME00339B (es)
MX (1) MXPA03005339A (es)
NO (2) NO334341B1 (es)
NZ (1) NZ526517A (es)
PT (1) PT1591121E (es)
RS (1) RS50414B (es)
RU (1) RU2286155C2 (es)
SK (1) SK288222B6 (es)
UA (1) UA77404C2 (es)
WO (1) WO2002047693A2 (es)
ZA (1) ZA200305342B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1591121B1 (en) * 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7589082B2 (en) * 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI547431B (zh) * 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
CA2712005C (en) * 2008-02-05 2014-04-15 Harbor Biosciences, Inc. Pharmaceutical solid state forms
CA2728889C (en) 2008-04-03 2016-06-14 Harbor Biosciences, Inc. Solid state forms of a pharmaceutical
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CN102793929B (zh) * 2012-09-07 2013-12-11 上海奥科达生物医药科技有限公司 一种制备稳定非晶态药物制剂的方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US20200129438A1 (en) * 2018-10-31 2020-04-30 Edenbridge Pharmaceuticals, LLC Finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2648700A (en) * 1946-11-02 1953-08-11 Searle & Co 2-methyl-2,7-dihydroxy-octahydrophenanthrene-1-propionic acid and derivatives thereof
US2636042A (en) * 1949-07-08 1953-04-21 S B Penick And Company Water-soluble hormone compounds
US2642427A (en) * 1951-08-01 1953-06-16 Abbott Lab Piperazine salts of cyclopentanopolyhydrophenanthrene-3-monosulfates
US2666066A (en) * 1951-09-28 1954-01-12 Abbott Lab Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates
US3032469A (en) * 1958-05-02 1962-05-01 Charles E Frosst & Company Long acting steroid compounds
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3691212A (en) * 1970-04-24 1972-09-12 British Drug Houses Ltd 17alpha-(1',3'-alkadiynyl)-17beta-acyloxy(17beta-aroyloxy) steroids
US4046874A (en) * 1974-02-13 1977-09-06 Mead Johnson & Company Soapless shave composition
US4511551A (en) * 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
EP0193871B1 (en) * 1985-03-07 1989-05-31 Teikoku Hormone Mfg. Co., Ltd. 2-oxa- or aza-pregnane compounds
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
US5344392A (en) * 1990-09-28 1994-09-06 Baxter International Inc. Method and apparatus for preparation of solutions from concentrates
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DK0542364T3 (da) * 1991-11-13 1996-03-11 Glaxo Canada Anordning til reguleret frigivelse
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
IT1270831B (it) * 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
PT956024E (pt) * 1996-07-26 2004-10-29 Wyeth Corp Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
CA2329005C (en) * 1998-04-17 2006-01-03 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
EP1591121B1 (en) * 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form

Also Published As

Publication number Publication date
NO20131334L (no) 2003-07-04
MXPA03005339A (es) 2004-03-26
IL156423A (en) 2010-04-29
KR100899032B1 (ko) 2009-05-21
PT1591121E (pt) 2009-07-20
ATE434439T1 (de) 2009-07-15
RS50414B (sr) 2009-12-31
NO20032708L (no) 2003-07-04
HUP0400646A2 (hu) 2004-06-28
IL156423A0 (en) 2004-01-04
UA77404C2 (en) 2006-12-15
HK1057174A1 (en) 2004-03-19
DE60139087D1 (de) 2009-08-06
HUP0400646A3 (en) 2012-08-28
CY1109404T1 (el) 2014-07-02
DK1591121T3 (da) 2009-10-05
US20110046099A1 (en) 2011-02-24
CR7022A (es) 2009-02-23
EP1361881A2 (en) 2003-11-19
ES2327538T3 (es) 2009-10-30
ZA200305342B (en) 2004-10-11
EP1361881B1 (en) 2005-10-26
HU230400B1 (hu) 2016-04-28
CN1489468A (zh) 2004-04-14
NO334341B1 (no) 2014-02-10
SK288222B6 (sk) 2014-09-04
AU2002227421B2 (en) 2007-08-23
US20110046095A1 (en) 2011-02-24
WO2002047693A3 (en) 2002-11-07
BG107958A (bg) 2004-11-30
NZ526517A (en) 2005-09-30
BRPI0116793B1 (pt) 2015-06-23
YU47903A (sh) 2006-08-17
EE05358B1 (et) 2010-12-15
BG66178B1 (bg) 2011-11-30
BRPI0116793B8 (pt) 2021-05-25
KR20030061856A (ko) 2003-07-22
US20140309204A1 (en) 2014-10-16
CA2431521A1 (en) 2002-06-20
MEP48808A (en) 2011-02-10
SK8802003A3 (en) 2004-04-06
DE60114467T2 (de) 2006-07-20
CZ306435B6 (cs) 2017-01-25
RU2003121240A (ru) 2005-02-10
ATE307591T1 (de) 2005-11-15
HK1083457A1 (en) 2006-07-07
AU2742102A (en) 2002-06-24
EE200300229A (et) 2003-08-15
CA2431521C (en) 2010-03-16
EP1591121A1 (en) 2005-11-02
DK1361881T3 (da) 2006-02-20
WO2002047693A2 (en) 2002-06-20
CN1290507C (zh) 2006-12-20
DE60114467D1 (de) 2005-12-01
RU2286155C2 (ru) 2006-10-27
US7867990B2 (en) 2011-01-11
ES2253451T3 (es) 2006-06-01
EP1591121B1 (en) 2009-06-24
US20020173669A1 (en) 2002-11-21
NO20032708D0 (no) 2003-06-13
BR0116793A (pt) 2004-01-27
ME00339B (me) 2011-05-10
CZ20031896A3 (en) 2004-03-17
CA2431521E (en) 2013-04-16

Similar Documents

Publication Publication Date Title
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
ECSP056095A (es) Métodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero
GT199900203A (es) Composiciones de celecoxib.
BRPI0713565B8 (pt) processo para fabricação de uma forma de dosagem oral sólida
BRPI0513141A (pt) composição para anel vaginal, e, processo de contracepção a longo prazo
AU2012293593A8 (en) Use of estetrol as emergency contraceptive
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
ECSP088796A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
BR0014142A (pt) Composição de vacina e método de empregar a mesma
ITMI20040367A1 (it) Processo per la preparazione di drospirenone
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
PE20060318A1 (es) Forma de administracion para la contracepcion hormonal
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
CL2008002027A1 (es) Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras.
CU23480B7 (es) Métodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero
GT200000202A (es) Composiciones farmaceuticas acido estabilizadas de la tizoxanida y la nitazoxanida
AR032585A1 (es) Procedimiento para preparar composiciones farmaceuticas en comprimidos de desintegracion rapida sustancialmente exentos de cristales del principio farmacologicamente activo provenientes de la modificacion de la estructura cristalina de dicho agente durante las operaciones de fabricacion de los mismo
BRPI0402077B8 (pt) nanocápsulas contendo princípios ativos lipofílicos, uso de nanocápsulas, composições farmacêuticas e processo de preparação de nanocápsulas